Biomarkers · Hematology
Platelet Count
U-shaped: both low and high values carry risk. In NHANES 1999–2018 with linked mortality to 2019, each standard deviation is associated with a hazard ratio of 0.99. U-shaped: slope not comparable
NHANES, our fit with 95% CIPublished curve
Hazard ratios relative to each curve's own reference value, so the two curves need not cross 1 at the same point. The dotted vertical line marks the NHANES median.
NHANES hazard per SD0.9995% CI 0.96–1.01 · 49,104 adults, 7,188 deaths
Published hazard ratio1.32top vs bottom quarter (95% CI 1.18–1.47) · Systematic Review and Meta-Analysis of General Population Cohorts
Where people sit
Population percentiles (10^3 cells/uL) by sex and age band. Cycle or source as recorded in the catalogue.
| Sex | Age | 5th | 25th | Median | 75th | 95th | n | Cycle / source |
|---|---|---|---|---|---|---|---|---|
| All | 20-39 | 160 | 207 | 245 | 289 | 369 | 2,710 | 2017-2018 |
| All | 40-59 | 153 | 199 | 236 | 280 | 356 | 2,670 | 2017-2018 |
| All | 60+ | 144 | 188 | 223 | 264 | 338 | 2,820 | 2017-2018 |
| All | all | 152 | 198 | 235 | 278 | 355 | 8,200 | 2017-2018 |
| Men | all | 145 | 188 | 223 | 263 | 334 | 3,980 | 2017-2018 |
| Women | all | 161 | 209 | 248 | 292 | 372 | 4,220 | 2017-2018 |
What studies found when this marker was changed
Effects on the biomarker reported in the cited studies. They describe what happened in those populations, not a recommendation for anyone. See all catalogued interventions.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| clinical | Essential thrombocythemia (JAK2 / CALR mutations) | +300 to +1000 × 10³/µL extreme thrombocytosis (>600 × 10³/µL) | clinical guideline | Arber DA, et al. Blood. 2016;127:2391-2405. |
| clinical | Severe immune thrombocytopenic purpura (ITP) or splenic sequestration | -150 to -280 × 10³/µL severe thrombocytopenia (<30 × 10³/µL) | clinical guideline | Neunert C, et al. Blood Adv. 2019;3:3829-3866. |
| nutraceutical | Dietary omega-3 fatty acids (EPA/DHA 2-3g/day) | Reduces platelet hyperactivity and thromboxane generation | meta-analysis | Gao LG, et al. Atherosclerosis. 2013;226:328-334. |
| pharmacologic | Aspirin (81-100 mg) / P2Y12 inhibitors (Clopidogrel) for platelet hyperreactivity | Suppresses thromboxane A2 and platelet aggregation by >90% | rct | Antithrombotic Trialists' Collaboration. BMJ. 2002;324:71-86. |
| pharmacologic | Thrombopoietin receptor agonists (Eltrombopag / Romiplostim) in immune thrombocytopenia | +50 to +150 × 10³/µL increase to safe hemostatic levels | rct | Cheng G, et al. Lancet. 2011;377:393-402. |
Sources
- Hazard curve: Recalculated from mortality_association (HR=1.32 quartile_extreme); per-SD log(HR)=0.2166.
- Vinholt PJ, et al. Platelet count is associated with all-cause mortality in the general population: a systematic review and meta-analysis. Thromb Haemost. 2016;115(5):981-990.
- Empirical curve: our Cox model with age and sex, NHANES 1999–2018 with linked mortality to 2019.